These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 27096596)
41. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Strati P; Schlette EJ; Solis Soto LM; Duenas DE; Sivina M; Kim E; Keating MJ; Wierda WG; Ferrajoli A; Kantarjian H; Estrov Z; Jain N; Thompson PA; Wistuba II; Burger JA Blood; 2020 Feb; 135(7):510-513. PubMed ID: 31895947 [No Abstract] [Full Text] [Related]
42. Ibrutinib in the real world patient: many lights and some shades. Ghia P; Cuneo A Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711 [No Abstract] [Full Text] [Related]
43. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665 [No Abstract] [Full Text] [Related]